对精选的印度草药的抗炎作用的分子见解
Saumya Upadhyay1, Rajan Swami2, Shweta Shrivastava3
1Department of Pharmacology, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682041, Kerala, India.
Journal of Ayurveda and integrative medicine
|March 28, 2025
概括
传统的印度草药在治疗慢性炎症方面表现有前途,为传统疗法提供天然替代品,副作用较少. 为了临床应用,需要进一步的研究.
科学领域:
- 药理学和民族植物学
- 自然产品化学 自然产品化学
- 免疫学 免疫学 免疫学
背景情况:
- 慢性炎症与许多疾病有关,包括关节炎,阿尔茨海默氏症和癌症.
- 目前的抗炎药物 (NSAID,皮质类固醇) 有局限性和副作用.
- 越来越需要自然,有效的抗炎治疗方法.
研究的目的:
- 审查选择的传统印度草药的抗炎潜力.
- 探索其抗炎作用背后的药理机制.
- 确定潜在的天然生物活性化合物用于药物开发.
主要方法:
- 对具有抗炎性质的传统印度草药的文献综述.
- 对涉及转录因子,信号级联和细胞因子释放的药理机制的分析.
- 详细检查了尼姆,黄和阿什瓦甘达等草药中的活性成分.
主要成果:
- 精选的印度草药 (尼姆,黄,阿什瓦甘达等) 显示出显著的抗炎性质.
- 这些草药调节关键的炎症通路,并减少促炎媒介.
- 这些植物中的活性化合物显示出治疗潜力.
结论:
- 传统的印度草药为新型抗炎疗法提供了有希望的来源.
- 了解它们的机制可以指导对炎症疾病的新治疗方法的开发.
- 进一步的研究是必要的,以验证这些发现,并使临床翻译.
相关概念视频
Combined Effects of Drugs: Antagonism
11.6K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.6K
Spasmolytic Agents: Chemical Classification
1.5K
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.5K
Analgesia and Pain Management
3.3K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.3K
Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880


